- Home
- SGA vs COCH Comparison
SGA vs COCH Comparison
Compare SGA & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGA | COCH |
|---|---|---|
| Founded | 1986 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Broadcasting | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.3M | 49.7M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGA | COCH |
|---|---|---|
| Price | $9.09 | $0.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 12.6K | ★ 124.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 9.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $124,829,000.00 | N/A |
| Revenue This Year | $6.74 | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.65 | N/A |
| 52 Week Low | $9.18 | $0.36 |
| 52 Week High | $14.27 | $1.89 |
Technical Indicators
Market Signals| Indicator | SGA | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 26.11 | 43.95 |
| Support Level | N/A | $0.64 |
| Resistance Level | $12.02 | $0.73 |
| Average True Range (ATR) | 0.28 | 0.04 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 5.95 | 17.54 |
Price Performance
Historical ComparisonAbout SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.